Unknown

Dataset Information

0

Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer.


ABSTRACT: An estimated 284,000 Americans will be diagnosed with breast cancer in 2021. Of these individuals, 15-20% have basal-like triple-negative breast cancer (TNBC), which is known to be highly metastatic. Chemotherapy is standard of care for TNBC patients, but chemoresistance is a common clinical problem. There is currently a lack of alternative, targeted treatment strategies for TNBC; this study sought to identify novel therapeutic combinations to treat basal-like TNBCs. For these studies, four human basal-like TNBC cell lines were utilized to determine the cytotoxicity profile of 1363 clinically-used drugs. Ten promising therapeutic candidates were identified, and synergism studies were performed in vitro. Two drug combinations that included KPT-330, an XPO1 inhibitor, were synergistic in all four cell lines. In vivo testing of four basal-like patient-derived xenografts (PDX) identified one combination, KPT-330 and GSK2126458 (a PI3K/mTOR inhibitor), that decreased tumor burden in mice significantly more than monotherapy with either single agent. Bulk and single-cell RNA-sequencing, immunohistochemistry, and analysis of published genomic datasets found that XPO1 was abundantly expressed in human basal-like TNBC cell lines, PDXs, and patient tumor samples. Within basal-like PDXs, XPO1 overexpression was associated with increased proliferation at the cellular level. Within patient datasets, XPO1 overexpression was correlated with greater rates of metastasis in patients with basal-like tumors. These studies identify a promising potential new combination therapy for patients with basal-like breast cancer.

SUBMITTER: Rashid NS 

PROVIDER: S-EPMC8512760 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer.

Rashid Narmeen S NS   Hairr Nicole S NS   Murray Graeme G   Olex Amy L AL   Leftwich Tess J TJ   Grible Jacqueline M JM   Reed Jason J   Dozmorov Mikhail G MG   Harrell J Chuck JC  

Translational oncology 20211007 12


An estimated 284,000 Americans will be diagnosed with breast cancer in 2021. Of these individuals, 15-20% have basal-like triple-negative breast cancer (TNBC), which is known to be highly metastatic. Chemotherapy is standard of care for TNBC patients, but chemoresistance is a common clinical problem. There is currently a lack of alternative, targeted treatment strategies for TNBC; this study sought to identify novel therapeutic combinations to treat basal-like TNBCs. For these studies, four huma  ...[more]

Similar Datasets

2021-10-20 | GSE174391 | GEO
| PRJNA729731 | ENA
| S-EPMC3127435 | biostudies-literature
| S-EPMC7649527 | biostudies-literature
| S-EPMC10618734 | biostudies-literature
| S-EPMC5582957 | biostudies-literature
| S-EPMC6534477 | biostudies-literature
| S-EPMC5342331 | biostudies-literature
| S-EPMC5995333 | biostudies-literature
2023-08-15 | GSE229428 | GEO